What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Mogamulizumab has not been directly compared with standard care used in the Healthcare, which limits the robustness of its clinical effectiveness evidence. The only direct comparison was with vorinostat, a treatment not available in the UK. While indirect comparisons suggest that mogamulizumab may improve overall survival, the evidence is uncertain due to potential biases and the lack of a common treatment to connect the trials.
Does the economic case hold at the expected price? — Cost effectiveness
The ICER for mogamulizumab is estimated at £28,233 per QALY gained, which is within the range typically considered acceptable by NICE. Despite some uncertainties in the cost-effectiveness analysis, the committee concluded that the estimates are likely acceptable for Healthcare resources.
Is there quality-of-life evidence payers weigh? — Quality of life
Patient experts reported significant improvements in quality of life, including reduced itching and better skin condition, allowing for easier daily activities. However, the evidence is primarily anecdotal and lacks robust quantitative measures, which tempers the strength of the claim.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Mogamulizumab has a good safety profile with mostly mild to moderate adverse events reported. Serious adverse events are rare, indicating that the treatment is generally well-tolerated compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator, vorinostat, is not used in the UK, and the evidence for standard care was derived from indirect comparisons. While standard care was deemed the most appropriate comparator, the lack of direct evidence limits the strength of the conclusions.
Is the population defined the way payers need it? — Patient Population and Subgroups
The population studied in the MAVORIC trial is relevant to the intended use of mogamulizumab, particularly the subgroup with severe disease. However, there are concerns about the representativeness of the trial population due to the lack of differentiation between mycosis fungoides and Szary syndrome.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Mogamulizumab can be integrated into existing treatment pathways with minor adjustments. The treatment does not require significant changes to infrastructure or training, making it a feasible option for healthcare providers.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of mogamulizumab is manageable, especially considering the commercial arrangement that provides a discount. The overall resource use is expected to be justifiable given the treatment’s benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the MAVORIC trial provides some robust evidence, the reliance on indirect comparisons and the absence of direct comparisons with standard care introduce significant uncertainties. The evidence base is not as strong as it could be.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the clinical effectiveness and cost-effectiveness of mogamulizumab, particularly due to the lack of direct comparisons with standard care. These uncertainties could impact the decision-making process.
